A Phase I Clinical Study of DSP-1181 for the Treatment of Obsessive-Compulsive Disorder
Latest Information Update: 05 Feb 2020
At a glance
- Drugs DSP 1181 (Primary)
- Indications Obsessive-compulsive disorders
- Focus Adverse reactions
Most Recent Events
- 05 Feb 2020 New trial record
- 30 Jan 2020 According to a Sumitomo Dainippon Pharma media release, this phase I study has been initiated in Japan for the treatment of obsessive-compulsive disorder as an initial indication.